Repligen Corp.

NAS: RGEN

GO
/marketstate/country/us

Market open

 --Real time quotes

Apr 9, 2020, 9:45 a.m.

/zigman2/quotes/210324360/lastsale

$

99.01

Change

+2.51 +2.60%

Volume

Volume 4,031

Real time quotes

/zigman2/quotes/210324360/lastsale

Previous close

$ 96.50

$ 99.01

Change

+2.51 +2.60%

Day low

Day high

$97.46

$99.01

Open

52 week low

52 week high

$52.87

$109.94

Open

Company Description

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products u...

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Valuation

P/E Current

222.12

P/E Ratio (with extraordinary items)

239.14

P/E Ratio (without extraordinary items)

212.60

Price to Sales Ratio

16.84

Price to Book Ratio

4.55

Price to Cash Flow Ratio

73.69

Enterprise Value to EBITDA

79.85

Enterprise Value to Sales

18.01

Total Debt to Enterprise Value

0.06

Efficiency

Revenue/Employee

355,118.00

Income Per Employee

28,135.00

Receivables Turnover

6.81

Total Asset Turnover

0.25

Liquidity

Current Ratio

13.28

Quick Ratio

12.15

Cash Ratio

11.12

Profitability

Gross Margin

51.15

Operating Margin

14.83

Pretax Margin

9.68

Net Margin

7.92

Return on Assets

1.97

Return on Equity

2.56

Return on Total Capital

3.93

Return on Invested Capital

2.21

Capital Structure

Total Debt to Total Equity

24.85

Total Debt to Total Capital

19.90

Total Debt to Total Assets

18.81

Long-Term Debt to Equity

24.51

Long-Term Debt to Total Capital

19.63

Officers and Executives

Name Age Officer Since Title
Mr. Tony J. Hunt 55 2014 President, Chief Executive Officer & Director
Mr. Steve Curran - 2015 Vice President-Global Operations
Mr. Jon K. Snodgres 53 2014 Secretary, Chief Financial & Accounting Officer
Mr. Ralf Kuriyel 60 2016 Senior Vice President-Research & Development
Mr. Vikas Gupta - 2016 Vice President-Strategy Growth Initiatives

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/03/2020 Nicolas M. Barthelemy
Director
2,688   Disposition at $99.99 per share. 268,773
04/03/2020 Nicolas M. Barthelemy
Director
1,652   Derivative/Non-derivative trans. at $42.07 per share. 69,499
03/24/2020 John G. Cox
Director
1,858   Disposition at $96.72 per share. 179,705
03/18/2020 John G. Cox
Director
1,016   Disposition at $97.17 per share. 98,724
03/18/2020 John G. Cox
Director
1,187   Disposition at $96.45 per share. 114,486
03/18/2020 John G. Cox
Director
24,533   Disposition at $95.13 per share. 2,333,824
03/18/2020 John G. Cox
Director
3,304   Derivative/Non-derivative trans. at $42.07 per share. 138,999
03/18/2020 John G. Cox
Director
2,434   Derivative/Non-derivative trans. at $38.76 per share. 94,341
03/18/2020 John G. Cox
Director
3,366   Derivative/Non-derivative trans. at $26.12 per share. 87,919
03/18/2020 John G. Cox
Director
3,632   Derivative/Non-derivative trans. at $41.19 per share. 149,602
03/18/2020 John G. Cox
Director
14,000   Derivative/Non-derivative trans. at $12.91 per share. 180,740
03/16/2020 Thomas F. Ryan
Director
1,000   Disposition at $91.48 per share. 91,480
03/16/2020 Thomas F. Ryan
Director
500   Derivative/Non-derivative trans. at $42.07 per share. 21,035
03/16/2020 Thomas F. Ryan
Director
500   Derivative/Non-derivative trans. at $38.76 per share. 19,380
03/04/2020 Tony J. Hunt
Chief Executive Officer; Director
12,300   Disposition at $90.13 per share. 1,108,599
03/04/2020 Jon K. Snodgres
Chief Financial Officer
1,045   Disposition at $90.39 per share. 94,457
03/04/2020 Ralf Kuriyel
Senior VP, R&D
1,905   Disposition at $90.99 per share. 173,335
03/04/2020 Ralf Kuriyel
Senior VP, R&D
650   Disposition at $90.08 per share. 58,552
03/04/2020 Thomas F. Ryan
Director
4,796   Disposition at $88.82 per share. 425,980
03/04/2020 John G. Cox
Director
10,000   Disposition at $93.39 per share. 933,900
03/04/2020 Thomas F. Ryan
Director
2,804   Derivative/Non-derivative trans. at $42.07 per share. 117,964
03/04/2020 Thomas F. Ryan
Director
1,992   Derivative/Non-derivative trans. at $41.19 per share. 82,050
03/04/2020 John G. Cox
Director
10,000   Derivative/Non-derivative trans. at $12.91 per share. 129,100
03/03/2020 Tony J. Hunt
Chief Executive Officer; Director
100   Disposition at $88.56 per share. 8,856
03/03/2020 Tony J. Hunt
Chief Executive Officer; Director
2,090   Disposition at $88.2 per share. 184,338
03/03/2020 Jon K. Snodgres
Chief Financial Officer
610   Disposition at $88.18 per share. 53,789
03/03/2020 Ralf Kuriyel
Senior VP, R&D
450   Disposition at $88.35 per share. 39,757
03/03/2020 Thomas F. Ryan
Director
2,225   Disposition at $85.72 per share. 190,727
02/27/2020 Tony J. Hunt
Chief Executive Officer; Director
18,583   Award at $0 per share. 0
02/27/2020 Jon K. Snodgres
Chief Financial Officer
4,686   Award at $0 per share. 0
02/27/2020 Ralf Kuriyel
Senior VP, R&D
3,216   Award at $0 per share. 0
02/26/2020 Tony J. Hunt
Chief Executive Officer; Director
1,594   Disposition at $86.1 per share. 137,243
02/26/2020 Tony J. Hunt
Chief Executive Officer; Director
1,881   Disposition at $86.86 per share. 163,383
02/26/2020 Jon K. Snodgres
Chief Financial Officer
946   Disposition at $86.11 per share. 81,460
02/26/2020 Jon K. Snodgres
Chief Financial Officer
154   Disposition at $86.86 per share. 13,376
02/26/2020 Ralf Kuriyel
Senior VP, R&D
195   Disposition at $86.6 per share. 16,887
02/25/2020 Tony J. Hunt
Chief Executive Officer; Director
10,210   Derivative/Non-derivative trans. at $16.55 per share. 168,975
02/25/2020 Tony J. Hunt
Chief Executive Officer; Director
11,735   Derivative/Non-derivative trans. at $32.4 per share. 380,214
02/25/2020 Tony J. Hunt
Chief Executive Officer; Director
1,624   Disposition at $90.22 per share. 146,517
02/25/2020 Tony J. Hunt
Chief Executive Officer; Director
8,412   Disposition at $91.66 per share. 771,043
02/25/2020 Tony J. Hunt
Chief Executive Officer; Director
1,699   Disposition at $92.34 per share. 156,885
02/24/2020 John G. Cox
Director
4,355   Disposition at $92.76 per share. 403,969
02/24/2020 John G. Cox
Director
100   Disposition at $94.85 per share. 9,485
/news/latest/company/us/rgen

MarketWatch News on RGEN

  1. Small-Cap ‘Darlings’ Are Perking Up in 2020

    11:47 a.m. Jan. 21, 2020

    - Barron's Online

  2. These 6 stocks in the S&P 1500 have more than doubled in 12 months

    7:28 a.m. July 13, 2019

    - Philip van Doorn

  3. Repligen started at overweight with $42 stock price target at J.P. Morgan

    8:28 a.m. Dec. 5, 2017

    - Tomi Kilgore

  4. Repligen stock fair value estimate raised to $47 from $42 at Janney

    11:26 a.m. June 23, 2017

    - Tomi Kilgore

  5. Repligen agrees to buy Spectrum in a cash-and-stock deal valued at $359 mln

    7:01 a.m. June 23, 2017

    - Tomi Kilgore

  6. Repligen's stock halted for news pending

    6:58 a.m. June 23, 2017

    - Tomi Kilgore

  7. Repligen's stock was inactive premarket prior to trading halt

    6:59 a.m. June 23, 2017

    - Tomi Kilgore

  8. Investing From the Ground Up

    12:13 a.m. Sept. 15, 2016

    - Barron's Online

  9. Why Danaher’s Purchase of Pall Means More M&A is on the Way

    11:39 a.m. May 13, 2015

    - Barrons Blogs

  10. Bull trend absorbs soft second-quarter start

    10:41 a.m. April 6, 2015

    - Michael Ashbaugh

  11. These are the most profitable Nasdaq biotech companies

    12:36 p.m. March 2, 2015

    - Philip van Doorn

  12. Here are the best-performing stocks so far in 2015

    12:47 p.m. Jan. 9, 2015

    - Philip van Doorn

  13. 13D Filings

    7:45 a.m. July 27, 2013

    - Barron's Online

  14. 13D Filings

    4:25 a.m. July 20, 2013

    - Barron's Online

  15. Loading more headlines...
/news/nonmarketwatch/company/us/rgen

Other News on RGEN

  1. Stocks To Watch: Investors Stay The Distance

    9:04 a.m. March 28, 2020

    - Seeking Alpha

  2. Repligen (RGEN) Receives a Buy from H.C. Wainwright

    7:13 a.m. March 23, 2020

    - SmarterAnalyst

  3. A Director at Repligen is Exercising Options

    3:50 a.m. March 19, 2020

    - SmarterAnalyst

  4. What Did This CEO Just Do with Personal Shares of Repligen (RGEN)?

    10:41 p.m. March 5, 2020

    - SmarterAnalyst

  5. A Director at Repligen is Exercising Options

    10:40 p.m. March 5, 2020

    - SmarterAnalyst

  6. The CFO of Repligen (RGEN) is Selling Shares

    10:15 p.m. Feb. 27, 2020

    - SmarterAnalyst

  7. A Director at Repligen (RGEN) is Selling Shares

    9:02 p.m. Feb. 26, 2020

    - SmarterAnalyst

  8. 10-K: REPLIGEN CORP

    4:55 p.m. Feb. 26, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  9. Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates

    10:14 a.m. Feb. 26, 2020

    - Zacks.com

  10. A Director at Repligen (RGEN) is Selling Shares

    10:23 p.m. Feb. 24, 2020

    - SmarterAnalyst

  11. Repligen (RGEN) Receives a Buy from Stephens

    9:59 a.m. Feb. 21, 2020

    - SmarterAnalyst

  12. Repligen slips 5% premarket after Q4 earnings

    8:22 a.m. Feb. 20, 2020

    - Seeking Alpha

  13. Notable earnings before Thursday's open

    5:30 p.m. Feb. 19, 2020

    - Seeking Alpha

  14. Loading more headlines...

At a Glance

Repligen Corp.

41 Seyon Street

Building 1

Suite 100

Waltham, Massachusetts 02453

Phone

1 7812500111

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$270.25M

Net Income

$21.41M

2019 Sales Growth

39.3%

Employees

761.00

/news/pressrelease/company/us/rgen

Press Releases on RGEN

  1. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.